Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02601248 |
Recruitment Status :
Completed
First Posted : November 10, 2015
Last Update Posted : February 13, 2020
|
Sponsor:
Hutchison Medipharma Limited
Information provided by (Responsible Party):
Hutchmed ( Hutchison Medipharma Limited )
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date ICMJE | October 14, 2013 | |||
First Posted Date ICMJE | November 10, 2015 | |||
Last Update Posted Date | February 13, 2020 | |||
Study Start Date ICMJE | October 2012 | |||
Actual Primary Completion Date | February 2016 (Final data collection date for primary outcome measure) | |||
Current Primary Outcome Measures ICMJE |
Safety :the incidence of all adverse events by type and grade, abnormal laboratory changes [ Time Frame: from day 1 of first dosing to 30days after permanent discontinuation of Thialitinib ] for each patient, adverse events are collected from the date of consent until 30 days after trial discontinuation
|
|||
Original Primary Outcome Measures ICMJE | Same as current | |||
Change History | ||||
Current Secondary Outcome Measures ICMJE |
|
|||
Original Secondary Outcome Measures ICMJE | Same as current | |||
Current Other Pre-specified Outcome Measures | Not Provided | |||
Original Other Pre-specified Outcome Measures | Not Provided | |||
Descriptive Information | ||||
Brief Title ICMJE | Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor | |||
Official Title ICMJE | Single Site, Open-label, Dose Escalation Phase I Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumors | |||
Brief Summary | First-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity(DLT), safety and tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of Theliatinib . | |||
Detailed Description | Theliatinib (HMPL-309) is a new constructive, high effective, high selective, EGFR tyrosine kinase inhibitor. Theliatinib has demonstrated strong inhibitory effects on multiple tumors with overexpressed EGFR or sensitive EGFR mutations. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity(DLT), safety and tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of Theliatinib . | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 1 | |||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
|||
Condition ICMJE | Cancer | |||
Intervention ICMJE | Drug: Theliatinib
Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
Other Name: HMPL-309
|
|||
Study Arms ICMJE | Experimental: Theliatinib
Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 5 dose cohorts,including120mg/160mg/200mg/220mg/300mg, QD in the dose escalation stage .
Intervention: Drug: Theliatinib
|
|||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE |
24 | |||
Original Estimated Enrollment ICMJE |
30 | |||
Actual Study Completion Date ICMJE | May 2016 | |||
Actual Primary Completion Date | February 2016 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
|||
Sex/Gender ICMJE |
|
|||
Ages ICMJE | 18 Years to 75 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | China | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT02601248 | |||
Other Study ID Numbers ICMJE | 2010-309-00CH1 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE |
|
|||
Current Responsible Party | Hutchmed ( Hutchison Medipharma Limited ) | |||
Original Responsible Party | Same as current | |||
Current Study Sponsor ICMJE | Hutchison Medipharma Limited | |||
Original Study Sponsor ICMJE | Same as current | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
|
|||
PRS Account | Hutchmed | |||
Verification Date | February 2020 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |